Changes in Beneficial Ownership · 4
Roivant Sciences Ltd.
ROIVNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1793139710.xml
Filing details
- Report period
- 2026-10-23
- Issuer
- Roivant Sciences Ltd.
- Issuer CIK
- 0001635088
- Trading symbol
- ROIV
Reporting owner 1
- Name
- MOMTAZEE JAMES C
- Reporting owner CIK
- 0001209181
- Relationship
- Director
- Address
- C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM, X0, SW1H 0DB
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Shares | 2026-10-23 | A · Form 4 | 383[F1] | A | 0[F1] | 112,342 | D |
| Common Shares | 2026-10-23 | F · Form 4 | 77[F2] | D | 36.49 | 112,265 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
- F · Form 4
- Securities delivered or withheld for exercise price or tax liability under Rule 16b-3
Footnotes
- F1
- Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.↩ 1↩ 2
- F2
- Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.↩ 1
Signature 1
- Signed
- By: /s/ Sam Kaplan, as Attorney-in-Fact for James C. Momtazee
- Date
- 2026-10-27
Company context
Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.